Compounds > moxifloxacin
Page last updated: 2024-09-04

moxifloxacin and methicillin

moxifloxacin has been researched along with methicillin in 5 studies

Compound Research Comparison

Studies
(moxifloxacin)		Trials
(moxifloxacin)		Recent Studies (post-2010)
(moxifloxacin)		Studies
(methicillin)		Trials
(methicillin)		Recent Studies (post-2010) (methicillin)
3,1575521,6904,375721,046

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (80.00)29.6817
2010's0 (0.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Lombardo, F; Obach, RS; Waters, NJ1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Giamarellou, H; Kyroudi, A; Papalois, A; Pefanis, A; Skiadas, I; Triantafyllidi, H; Tsaganos, T1
Citron, DM; Goldstein, EJC; Rybak, MJ; Tyrrell, KL; Warren, YA1
Akbar, N; Jabri, T; Kawish, M; Khan, NA; Shah, MR; Siddiqui, R1

Other Studies

5 other study(ies) available for moxifloxacin and methicillin

ArticleYear
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Dexamethasone as adjuvant therapy to moxifloxacin attenuates valve destruction in experimental aortic valve endocarditis due to Staphylococcus aureus.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:8

    Topics: Adjuvants, Immunologic; Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Aortic Valve; Aza Compounds; Dexamethasone; Disease Models, Animal; Echocardiography; Endocarditis, Bacterial; Fluoroquinolones; Humans; Methicillin; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome

2007
Virulence characteristics of community-associated Staphylococcus aureus and in vitro activities of moxifloxacin alone and in combination against community-associated and healthcare-associated meticillin-resistant and -susceptible S. aureus.
    Journal of medical microbiology, 2008, Volume: 57, Issue:Pt 4

    Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Proteins; Community-Acquired Infections; Cross Infection; Drug Synergism; Drug Therapy, Combination; Fluoroquinolones; Humans; Methicillin; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Soft Tissue Infections; Staphylococcal Infections; Staphylococcal Skin Infections; Staphylococcus aureus; Virulence; Virulence Factors

2008
Enhancing efficacy of existing antibacterials against selected multiple drug resistant bacteria using cinnamic acid-coated magnetic iron oxide and mesoporous silica nanoparticles.
    Pathogens and global health, 2022, Volume: 116, Issue:7

    Topics: Anti-Bacterial Agents; Cefixime; Cinnamates; Escherichia coli; Ferric Compounds; Humans; Lactate Dehydrogenases; Magnetic Phenomena; Methicillin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Nanoparticles; Prospective Studies; Silicon Dioxide; Sulfamethoxazole

2022